Trinity Biotech (TRIB) Competitors $0.80 +0.03 (+3.90%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. LPCN, LVTX, NAII, PLUR, ENLV, EQ, AKTX, CMMB, SNTI, and LSBShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Lipocine (LPCN), LAVA Therapeutics (LVTX), Natural Alternatives International (NAII), Pluri (PLUR), Enlivex Therapeutics (ENLV), Equillium (EQ), Akari Therapeutics (AKTX), Chemomab Therapeutics (CMMB), Senti Biosciences (SNTI), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Lipocine LAVA Therapeutics Natural Alternatives International Pluri Enlivex Therapeutics Equillium Akari Therapeutics Chemomab Therapeutics Senti Biosciences Lakeshore Biopharma Lipocine (NASDAQ:LPCN) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk. Which has higher earnings & valuation, LPCN or TRIB? Lipocine has higher earnings, but lower revenue than Trinity Biotech. Lipocine is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$7.92M3.29-$16.35M-$0.76-6.41Trinity Biotech$59.13M0.10-$24.02M-$2.26-0.35 Does the media prefer LPCN or TRIB? In the previous week, Lipocine had 3 more articles in the media than Trinity Biotech. MarketBeat recorded 6 mentions for Lipocine and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.49 beat Lipocine's score of 0.23 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in LPCN or TRIB? Lipocine received 12 more outperform votes than Trinity Biotech when rated by MarketBeat users. However, 72.04% of users gave Trinity Biotech an outperform vote while only 69.26% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34769.26% Underperform Votes15430.74% Trinity BiotechOutperform Votes33572.04% Underperform Votes13027.96% Is LPCN or TRIB more profitable? Lipocine has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -19.17% -17.60% Trinity Biotech -34.39%N/A -21.37% Which has more risk & volatility, LPCN or TRIB? Lipocine has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Do analysts recommend LPCN or TRIB? Lipocine currently has a consensus target price of $10.00, suggesting a potential upside of 105.34%. Given Lipocine's stronger consensus rating and higher possible upside, equities analysts clearly believe Lipocine is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of LPCN or TRIB? 9.1% of Lipocine shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 6.1% of Lipocine shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryLipocine beats Trinity Biotech on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.10M$2.51B$5.13B$9.07BDividend YieldN/A0.73%5.08%4.23%P/E Ratio-0.356.0789.5817.17Price / Sales0.1075.121,116.12116.95Price / CashN/A15.0542.8237.86Price / Book-0.253.284.774.78Net Income-$24.02M$29.98M$120.15M$225.60M7 Day Performance-11.60%-1.55%-1.92%-1.23%1 Month Performance-38.46%8.21%11.47%3.36%1 Year Performance-64.52%-21.46%30.54%16.60% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.4268 of 5 stars$0.80+3.9%N/A-67.3%$6.10M$59.13M-0.35480News CoverageLPCNLipocine1.531 of 5 stars$4.96-1.2%$10.00+101.6%+63.4%$26.53M$7.92M-6.6110News CoverageLVTXLAVA Therapeutics3.0647 of 5 stars$1.03-7.2%$4.67+353.1%-31.3%$26.11M$7.35M-1.0860Analyst ForecastGap DownNAIINatural Alternatives InternationalN/A$4.21-2.1%N/A-37.1%$26.10M$112.98M-2.99290Analyst ForecastPLURPluri0.4281 of 5 stars$4.62-2.1%N/A+10.5%$25.69M$330,000.000.00150News CoveragePositive NewsENLVEnlivex Therapeutics2.3234 of 5 stars$1.18-1.7%$9.50+705.1%-36.6%$25.26MN/A0.0070EQEquillium2.9048 of 5 stars$0.68-3.2%$5.00+633.0%-16.5%$24.17M$45.91M-5.0440Gap DownAKTXAkari TherapeuticsN/A$0.97-0.3%N/A-67.2%$24.02MN/A0.009Analyst ForecastGap DownCMMBChemomab Therapeutics3.3163 of 5 stars$1.65+4.4%$7.33+344.4%+230.1%$23.69MN/A-1.5820Positive NewsSNTISenti Biosciences2.3435 of 5 stars$5.12-8.1%$10.00+95.3%-5.2%$23.50M$2.56M-0.334News CoverageGap DownLSBLakeshore Biopharma0.5004 of 5 stars$2.50+0.4%N/AN/A$23.28M$80.82M0.00773News CoverageGap Up Related Companies and Tools Related Companies Lipocine Competitors LAVA Therapeutics Competitors Natural Alternatives International Competitors Pluri Competitors Enlivex Therapeutics Competitors Equillium Competitors Akari Therapeutics Competitors Chemomab Therapeutics Competitors Senti Biosciences Competitors Lakeshore Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRIB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
